Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Total Liabilities (2020 - 2025)

Maravai Lifesciences Holdings has reported Total Liabilities over the past 6 years, most recently at $397.9 million for Q4 2025.

  • Quarterly results put Total Liabilities at $397.9 million for Q4 2025, down 7.7% from a year ago — trailing twelve months through Dec 2025 was $397.9 million (down 7.7% YoY), and the annual figure for FY2025 was $397.9 million, down 7.7%.
  • Total Liabilities for Q4 2025 was $397.9 million at Maravai Lifesciences Holdings, down from $417.3 million in the prior quarter.
  • Over the last five years, Total Liabilities for MRVI hit a ceiling of $1.4 billion in Q3 2021 and a floor of $397.9 million in Q4 2025.
  • Median Total Liabilities over the past 5 years was $1.2 billion (2021), compared with a mean of $987.9 million.
  • Biggest five-year swings in Total Liabilities: rose 23.03% in 2021 and later crashed 52.84% in 2024.
  • Maravai Lifesciences Holdings' Total Liabilities stood at $1.4 billion in 2021, then rose by 0.3% to $1.4 billion in 2022, then crashed by 49.34% to $697.6 million in 2023, then plummeted by 38.21% to $431.0 million in 2024, then decreased by 7.7% to $397.9 million in 2025.
  • The last three reported values for Total Liabilities were $397.9 million (Q4 2025), $417.3 million (Q3 2025), and $429.0 million (Q2 2025) per Business Quant data.